(RTTNews) – Edwards Lifesciences Corp. (EW) said that one-year results on patients treated in TRISCEND study of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.
Patients enrolled in the TRISCEND study had symptomatic moderate or greater functional or degenerative tricuspid regurgitation (TR), despite optimal medical therapy.
The one-year outcomes demonstrated high survival of 90.1% and high freedom from heart failure hospitalization at 88.4%; significant and sustained TR reduction, with 97.6% of patients with mild or trace TR (n=84).
The data also demonstrated significantly improved functional and quality-of-life outcomes, with 93% of patients in NYHA Class I or II compared to 26% at baseline (n=89) and a 26-point increase in KCCQ score over baseline (n=102).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
